SIENDO): Impact of subgroup analysis and molecular classification.

Overview of attention for article published in Journal of Clinical Oncology, June 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 5 news outlets

twitter: 1 X user

Readers on

mendeley: 15 Mendeley

So far, Altmetric has seen 5 news stories from 5 outlets.

Despite Early Success, Karyopharm’s Selinexor Faces Uncertain Path ...

BioSpace, 18 Sep 2023

Pictured: a bone marrow slide showing multiple myeloma/iStock, Md Saiful Islam Khan Ever since Karyopharm Therapeutics gained…

Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away

Seeking Alpha, 21 Aug 2023

Summary Karyopharm Therapeutics reported $37.6 million in total revenue, with a net loss of $32.6 million.

Study: Selinexor Shows Improved Progression-Free Survival in Endometrial Cancers

Pharmacy Times, 08 Jun 2022

Investigators found that individuals receiving selinexor had a median PFS of 5.7 months compared to 3.8 months for those given…

Selinexor Yields PFS Improvement in Advanced Endometrial Cancer Vs Placebo

Cancer Network, 07 Jun 2022

Patients enrolled on the phase 3 ENGOT-EN5/GOG-3055/SIENDO study with advanced or recurrent endometrial cancer appeared to…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.